This held true when only breast cancer cells harboring PIK3CA-activating mutations, which are known to be sensitive to PI3Kα inhibition (Elkabets et al., 2013), were considered in the analysis (Figures 3B and 3C). This evidence concerns the gene PIK3CA and breast cancer.